AU2001236641A1 - Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors - Google Patents

Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors

Info

Publication number
AU2001236641A1
AU2001236641A1 AU2001236641A AU3664101A AU2001236641A1 AU 2001236641 A1 AU2001236641 A1 AU 2001236641A1 AU 2001236641 A AU2001236641 A AU 2001236641A AU 3664101 A AU3664101 A AU 3664101A AU 2001236641 A1 AU2001236641 A1 AU 2001236641A1
Authority
AU
Australia
Prior art keywords
patient
therapy
tumor
cancer cells
irradiated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236641A
Inventor
Bruce W. Lyday
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRIAD IMMUNOLOGIES LLC
Original Assignee
TRIAD IMMUNOLOGIES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRIAD IMMUNOLOGIES LLC filed Critical TRIAD IMMUNOLOGIES LLC
Publication of AU2001236641A1 publication Critical patent/AU2001236641A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An improved method of inducing whole-body hyperthermia and enhanced anti-tumor immune response through inoculation of a fever virus with nil mortality and subsequent injection of irradiated tumor cells derived from the patient. This therapy will safely reduce the tumor burden by 90-99.9% by physical means (fever), before raising interferon levels to over 250 times baseline. The Activated Lymphokine Killer cells produced by these high interferon levels are capable of killing any cell expressing viral or tumor antigens, even those which had previously escaped immune surveillance. As a final step in the process, a specific class of Cytotoxic T Lymphocytes programmed to destroy the patient's own cancer cells will be produced by repeated inoculation of irradiated cancer cells harvested from the patient. Through a combination of three methods of therapy never previously integrated into a single regimen, it is logical to state that this therapy has a high probability of completely eradicating cancer cells from the patient. In addition, this therapy provides for life-long immunity to the reoccurrence of the disease.
AU2001236641A 2000-02-04 2001-02-02 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors Abandoned AU2001236641A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/499,050 US6524587B1 (en) 1998-05-05 2000-02-04 Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
US09499050 2000-02-04
PCT/US2001/003565 WO2001056599A2 (en) 2000-02-04 2001-02-02 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors

Publications (1)

Publication Number Publication Date
AU2001236641A1 true AU2001236641A1 (en) 2001-08-14

Family

ID=23983612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236641A Abandoned AU2001236641A1 (en) 2000-02-04 2001-02-02 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors

Country Status (9)

Country Link
US (1) US6524587B1 (en)
EP (1) EP1261693B1 (en)
JP (1) JP2004507445A (en)
AT (1) ATE309329T1 (en)
AU (1) AU2001236641A1 (en)
CA (1) CA2398915A1 (en)
DE (1) DE60114780T2 (en)
ES (1) ES2250359T3 (en)
WO (1) WO2001056599A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10201856A1 (en) * 2002-01-18 2003-07-31 Eppendorf Ag Method for treating the surface of cells presenting antigens
JP2006519784A (en) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド Treatment for primary and metastatic cancers (A2) Hyperthermia and oncolysis (A3)
WO2005079820A1 (en) * 2004-02-23 2005-09-01 Ttc Co., Ltd. Immunopotentiator
JP2018522880A (en) * 2015-07-02 2018-08-16 プライムヴァックス イミュノ−オンコロジー，インク． Compositions and methods for combination therapy with dengue virus and dendritic cells
JP2018535191A (en) * 2015-09-26 2018-11-29 プライムヴァックス イミュノ−オンコロジー，インク． Compositions and methods for producing dendritic cells
CA3082779A1 (en) * 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN110831620A (en) * 2017-05-26 2020-02-21 埃特彼塞斯公司 Combination immunotherapy comprising IL-15 superagonists
EA201992863A1 (en) * 2017-06-15 2020-05-06 Праймвакс Иммуно-Онколоджи, Инк. COMPOSITIONS AND METHODS OF ANTI-CANCER THERAPY USING THE MONEY VIRUS AND DENDRITIC CELLS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1071450A2 (en) * 1998-04-23 2001-01-31 Arch Development Corporation Combination of antigen pulsed apcs and interleukin 12 for tumour and viral therapy
US6048686A (en) * 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer

Also Published As

Publication number Publication date
ATE309329T1 (en) 2005-11-15
DE60114780T2 (en) 2006-08-03
CA2398915A1 (en) 2001-08-09
EP1261693B1 (en) 2005-11-09
WO2001056599A2 (en) 2001-08-09
WO2001056599A3 (en) 2002-03-07
DE60114780D1 (en) 2005-12-15
EP1261693A2 (en) 2002-12-04
JP2004507445A (en) 2004-03-11
ES2250359T3 (en) 2006-04-16
US6524587B1 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
Huang et al. Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view
CA2033640A1 (en) Vaccines against cancer and infectious diseases
Chen et al. Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment
WO2004032865A3 (en) Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
AU2001236641A1 (en) Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
DE60137146D1 (en) FUSION CELLS AND CYTOKINE COMPOSITIONS FOR THE TREATMENT OF DISEASES
CA2405458A1 (en) Herpes viruses for immune modulation
Liang et al. Resistance to murine leukemia in mice receiving simultaneous injections of syngeneic hybrid and parental neoplastic cells
Trentin et al. Bone marrow transplantation immunology
Lollini et al. Immunoprevention and immunotherapy of mammary carcinoma
Habib et al. Letter to Editor: Challenges in the Development of Hepatitis C Vaccine
Kohl Additive effects of acyclovir and immune transfer in neonatal herpes simplex virus infection in mice
US12115188B2 (en) Supernatant from a coculture of macrophages and irradiated leukocytes, for controlling tumour progression or restoring anti-tumor immunity
CN103372203A (en) Antigen composition, preparation method and application of antigen composition and tumour vaccine
DE60033955D1 (en) MELANOMA VACCINE AND ITS MANUFACTURE AND USE
Mohr et al. Enhancement of a Tumor Allograft in BALB/c× DBA/2 F1 Mice by Pyran Copolymer
Levy Polynucleotides as interferon inducers and immune modulators
Puri et al. Cancer vaccines: a newer front of immunotherapy
Santini et al. Increasing antigenecity of B16 melanoma cell fraction with microwave hyperthermia
RU2203683C1 (en) Method for immunotherapy with medullary dendrite cells in patients with solid tumors
Brendel et al. 6.2 Immunosuppressive Therapy with Anti-lymphocytic Globulin and Tumor Formation
Song Advances in Cancer Immunotherapy: Enhancing the Immune Response and Addressing Therapeutic Challenges
von Heyden et al. Engrafted human bone marrow and blood cells in culture